Graphene Oxides Decorated with Carnosine as an Adjuvant To Modulate Innate Immune and Improve Adaptive Immunity in Vivo

• Published in: ACS nano 2016-02, Vol.10 (2), p.2203-2213
• Main Authors: Meng, Chunchun, Zhi, Xiao, Li, Chao, Li, Chuanfeng, Chen, Zongyan, Qiu, Xusheng, Ding, Chan, Ma, Lijun, Lu, Hongmin, Chen, Di, Liu, Guangqing, Cui, Daxiang
• Format: Article
• Language: English
• Subjects: Adaptive Immunity - drug effects; Adjuvants, Immunologic - chemistry; Adjuvants, Immunologic - pharmacokinetics; Adjuvants, Immunologic - pharmacology; Animals; Body Weight - drug effects; Carnosine - chemistry; Carnosine - immunology; Carnosine - pharmacology; Cytokines - blood; Graphite - chemistry; Graphite - immunology; Graphite - pharmacology; Immunity, Innate - drug effects; Male; Mice; Mice, Inbred BALB C; Organ Size - drug effects; Ovalbumin - immunology; Tissue Distribution
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.5b06750

Current studies have revealed the immune effects of graphene oxide (GO) and have utilized them as vaccine carriers and adjuvants. However, GO easily induces strong oxidative stress and inflammatory reaction at the site of injection. It is very necessary to develop an alternative adjuvant based on graphene oxide derivatives for improving immune responses and decreasing side effects. Carnosine (Car) is an outstanding and safe antioxidant. Herein, the feasibility and efficiency of ultrasmall graphene oxide decorated with carnosine as an alternative immune adjuvant were explored. OVA@GO-Car was prepared by simply mixing ovalbumin (OVA, a model antigen) with ultrasmall GO covalently modified with carnosine (GO-Car). We investigated the immunological properties of the GO-Car adjuvant in model mice. Results show that OVA@GO-Car can promote robust and durable OVA-specific antibody response, increase lymphocyte proliferation efficiency, and enhance CD4+ T and CD8+ T cell activation. The presence of Car in GO also probably contributes to enhancing the antigen-specific adaptive immune response through modulating the expression of some cytokines, including IL-6, CXCL1, CCL2, and CSF3. In addition, the safety of GO-Car as an adjuvant was evaluated comprehensively. No symptoms such as allergic response, inflammatory redness swelling, raised surface temperatures, physiological anomalies of blood, and remarkable weight changes were observed. Besides, after modification with carnosine, histological damages caused by GO-Car in lung, muscle, kidney, and spleen became weaken significantly. This study sufficiently suggest that GO-Car as a safe adjuvant can effectively enhance humoral and innate immune responses against antigens in vivo.